MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Thermo Fisher Scientific Inc

Fermé

SecteurSoins de santé

489.21 1.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

480.45

Max

491.12

Chiffres clés

By Trading Economics

Revenu

194M

1.8B

Ventes

795M

11B

P/E

Moyenne du Secteur

30.121

63.778

BPA

6.1

Rendement du dividende

0.35

Marge bénéficiaire

16.007

Employés

125,000

EBITDA

377M

3B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+38.06% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.35%

2.39%

Prochains Résultats

23 avr. 2025

Date du Prochain Dividende

15 avr. 2025

Date du Prochain Détachement de Dividende

13 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-40B

189B

Ouverture précédente

487.79

Clôture précédente

489.21

Sentiment de l'Actualité

By Acuity

33%

67%

106 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Thermo Fisher Scientific Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 févr. 2025, 14:05 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30 janv. 2025, 11:43 UTC

Résultats

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23 oct. 2024, 10:43 UTC

Résultats

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25 févr. 2025, 14:09 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25 févr. 2025, 13:41 UTC

Acquisitions, Fusions, Rachats

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25 févr. 2025, 13:40 UTC

Acquisitions, Fusions, Rachats

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25 févr. 2025, 13:40 UTC

Acquisitions, Fusions, Rachats

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25 févr. 2025, 13:40 UTC

Acquisitions, Fusions, Rachats

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25 févr. 2025, 13:40 UTC

Acquisitions, Fusions, Rachats

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25 févr. 2025, 13:39 UTC

Acquisitions, Fusions, Rachats

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25 févr. 2025, 13:33 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25 févr. 2025, 13:32 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25 févr. 2025, 13:32 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24 févr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24 févr. 2025, 23:03 UTC

Actualités
Acquisitions, Fusions, Rachats

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24 févr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Deal Could be Announced This Week, Sources Say -- WSJ

24 févr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30 janv. 2025, 11:06 UTC

Résultats

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30 janv. 2025, 11:05 UTC

Résultats

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30 janv. 2025, 11:00 UTC

Résultats

Thermo Fisher 4Q Rev $11.4B >TMO

30 janv. 2025, 11:00 UTC

Résultats

Thermo Fisher 4Q EPS $4.78 >TMO

30 janv. 2025, 11:00 UTC

Résultats

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30 janv. 2025, 11:00 UTC

Résultats

Thermo Fisher 4Q Net $1.83B >TMO

30 janv. 2025, 11:00 UTC

Résultats

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16 déc. 2024, 22:03 UTC

Actualités

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23 oct. 2024, 10:02 UTC

Résultats

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23 oct. 2024, 10:02 UTC

Résultats

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23 oct. 2024, 10:00 UTC

Résultats

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23 oct. 2024, 10:00 UTC

Résultats

Thermo Fisher 3Q EPS $4.25 >TMO

23 oct. 2024, 10:00 UTC

Résultats

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Comparaison

Variation de prix

Thermo Fisher Scientific Inc prévision

Objectif de Prix

By TipRanks

38.06% hausse

Prévisions sur 12 Mois

Moyen 666.81 USD  38.06%

Haut 715 USD

Bas 570 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

14

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 513.14Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

106 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar